Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics Study of Cefazolin in Hemodialysis
NCT06093269Phase 4Active, not recruiting
- Sponsor
- University Hospital Tours
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cefazolin in Bacteremia and hemodialysis catheter infection (CRBSI), sponsored by University Hospital Tours. Primary endpoint: Time during which cefazolin plasma concentration exceeds the target concentration of 40 mg/L at 48 hours. Started Nov 2023; status: active, not recruiting.
02
Drugs
cefazolin
03
Conditions
Bacteremiahemodialysis catheter infection (CRBSI)
Beyond the preview
Go deeper on NCT06093269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06093269.